Tropisetron

Tropisetron
Clinical data
Trade names	Navoban
Other names	ICS 205-930
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: B3; ;
Routes of; administration	Oral, IV
ATC code	A04AA03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: Not available or approved;
Pharmacokinetic data
Bioavailability	~60–80%
Protein binding	71%
Metabolism	Hepatic (CYP3A4, CYP1A2, CYP2D6)
Elimination half-life	6–8 hours
Excretion	Renal, Fecal
Identifiers
	IUPAC name (1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl 1methyl-indole-3-carboxylate;
CAS Number	89565-68-4 ;
PubChem CID	72165;
IUPHAR/BPS	260;
DrugBank	DB11699;
ChemSpider	16736476 ;
UNII	6I819NIK1W;
KEGG	D02130 ;
ChEBI	CHEBI:32269 ;
ChEMBL	ChEMBL496980 ;
CompTox Dashboard (EPA)	DTXSID2044137 ;
Chemical and physical data
Formula	C17H20N2O2
Molar mass	284.359 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN4[C@@H]1CC[C@H]4C[C@H](C1)OC(=O)c3c[nH]c2ccccc23;
	InChI InChI=1S/C17H20N2O2/c1-19-11-6-7-12(19)9-13(8-11)21-17(20)15-10-18-16-5-3-2-4-14(15)16/h2-5,10-13,18H,6-9H2,1H3/t11-,12+,13+ ; Key:ZNRGQMMCGHDTEI-ITGUQSILSA-N ;
	(what is this?) (verify)

Tropisetron is a serotonin 5-HT₃ receptor antagonist used mainly as an antiemetic to treat nausea and vomiting following chemotherapy, although it has been used experimentally as an analgesic in cases of fibromyalgia.^[1]

It was patented in 1982 and approved for medical use in 1992.^[2] It is on the World Health Organization's List of Essential Medicines.^[3] It is marketed by Novartis in Europe, Australia, New Zealand, Japan, South Korea and the Philippines as Navoban, but is not available in the U.S. It is also available from Novell Pharmaceutical Laboratories and marketed in several Asian countries as Setrovel.

^ Müller W, Stratz T (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scandinavian Journal of Rheumatology. Supplement. 119 (119): 44–48. doi:10.1080/03009740410007032. PMID 15515413. S2CID 24916914.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 448. ISBN 9783527607495.
^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[pain-1] Müller W, Stratz T (2004). "Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron". Scandinavian Journal of Rheumatology. Supplement. 119 (119): 44–48. doi:10.1080/03009740410007032. PMID 15515413. S2CID 24916914.

[2] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 448. ISBN 9783527607495.

[WHO22nd-3] World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.

[1]

[2]

[3]